Skip to main content

Lexaria Bioscience Corp.

LEXX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001348362

No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Lexaria Bioscience Corp. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of LEXX: Q3 2024 compared with Q4 2024
MeasureQ3 2024Of which not filed for Q4 2024Q4 2024Change
Holders27125−1
Shares1.07M44.9K1.44M+419.7K (+41.1%)
Value$3.25M$136.9K$3.03M−$89.0K (−2.9%)

1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (5)

Institutions that held Lexaria Bioscience Corp. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to LEXX in Q4 2024
InstitutionSharesValue% of portfolio
Armistice Capital, LLC460,000$966.0K0.02%
Raymond James Financial Inc60,640$127.3K0.00%
Scotia Capital Inc.10,000$21.0K0.00%
R Squared Ltd2,620$5.50K0.01%
UBS Group AG116$2440.00%

Sold out (6)

Institutions that held Lexaria Bioscience Corp. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of LEXX in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
GenTrust, LLC60,000$183.0K
Welch Group, LLC24,000$73.2K
XTX Topco Ltd18,626$56.8K
HRT Financial LP10,257$31.0K
Aspire Private Capital, LLC400$1.22K
Northwestern Mutual Wealth Management Co9$27

Not filed for Q4 2024 yet (1)

Institutions that held Lexaria Bioscience Corp. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding LEXX in Q3 2024 that haven't filed for Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Raymond James Financial Services Advisors, Inc.44,900$136.9K